Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin
derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators
will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus
Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung
cancer.
Primary endpoints
- to assess Response Rate
Secondary endpoints
- to assess Overall response duration, Time to progression, Overall survival